The Nurse View.

Slides:

Advertisements

Similar presentations

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.

Advertisements

Bladder Cancer: A New Era in Treatment

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

State of the Art in BRCA-Mutated Ovarian Cancer

Chronic HCV Infection and CKD

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

New Psoriasis Treatments

Please note this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Applying Biosimilars in Hematologic Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Advances in Managing Inhibitors in Patients With Hemophilia A

Relapsed/Refractory Follicular Lymphoma Conundrums

Dual Antiretroviral Therapy

Progression After Cancer Immunotherapy in Advanced NSCLC

New Standards of Care in ALK-Translocated Advanced NSCLC

Improving Acne Outcomes

Mid-Year Hemophilia Update

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Current and Future Goals in the Treatment of Relapsed CLL

Treating Transplant-Ineligible Patients With Multiple Myeloma

Assessing Newer Treatment Approaches for Multiply Relapsed Multiple Myeloma.

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

The Resurgence of Topical Treatments Across a Spectrum of Psoriasis

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

The Evolving Role of Immunotherapy in NSCLC

Optimizing Management of Advanced Bladder Cancer

Individualizing Care in Ovarian Cancer

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Next-Gen Psoriasis Therapies:

Evaluating Next-Generation BTK Inhibitors

Case Studies in Unresectable Hepatocellular Carcinoma

Navigating New Oral Treatment Algorithms in CLL

Targeting BTK Signaling in B-Cell Malignancies

Managing Adverse Events With New Oral Therapies in CLL

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Optimizing Outcomes and Managing Adverse Events in CLL

Immunotherapy for cSCC

The JAK-STAT Pathway and Graft-vs-Host Disease

Optimizing Frontline Care for Older Patients With Multiple Myeloma

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

How to Select Therapy In Newly Diagnosed CLL

Advancing Care Across the Spectrum of Pancreatic Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Updates in the Management of Acute Promyelocytic Leukemia

Getting to Grips With the Science of CGRP and Migraine

Advances in Immunotherapy for Peanut Allergy

Locally Advanced Lung Cancer

Guide to Atopic Dermatitis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Managing Your Patient’s Maintenance Therapy for Multiple Myeloma

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Evaluating BTK Inhibitors in CLL

The Psychiatrist's Role in Tardive Dyskinesia

Managing CLL With BTK Inhibitors

Novel Concepts in the Management of RCC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

From Adjuvant to Metastatic in Melanoma

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

Prioritizing Prevention of HPV-Related Disease

The Psychiatrist's Role in Tardive Dyskinesia

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

Checkpoint Inhibitors in First-Line Advanced NSCLC

VKA Reversal and LVADs.

How to Select Therapy in Relapsed/Refractory CLL

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Mitigating Side Effects and Optimizing Compliance With Oral Therapies in CLL.

Immune Checkpoint Inhibitors in Lung Cancer

Presentation transcript:

The Nurse View

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Current BTK Inhibitors

RESONATE Ibrutinib in Previously Treated CLL

RESONATE-2 Ibrutinib in Previously Untreated CLL

Ibrutinib in R/R MCL

Toxicities Most Commonly Causing Ibrutinib Discontinuation in a Real-World Setting

Acalabrutinib: A More Selective BTK Inhibitor Phase 2 Study in CLL

Acalabrutinib in MCL

Acalabrutinib Pooled Safety Analysis (N = 610)

Nursing Management Tips Diarrhea

Nursing Management Tips Hypertension, AF, and Bleeding

Nursing Management Tips Myalgia and Fatigue

Adherence With Oral Therapy

Interprofessional Communication Is Essential

Tips for Communicating With Patients

Key Takeaways

Abbreviations

Abbreviations (cont)